NMPA (China) approves Tuoyi to treat unresectable locally advanced/ recurrent or distant metastatic esophageal squamous cell carcinoma.
This announcement is made by Shanghai Junshi Biosciences Co., Ltd. on a voluntary basis.
Reference is also made to the overseas regulatory announcement of the Company dated 16 May 2022. The board of directors of the Company is pleased to announce that the Company has received the Drug Registration Certificate issued by the National Medical Products Administration (the “NMPA”). The supplemental new drug application (the “sNDA”) for toripalimab (trade name: Tuoyi product code: JS001) in combination with paclitaxel and cisplatin in the first-line treatment of patients with unresectable locally advanced/ recurrent or distant metastatic esophageal squamous cell carcinoma (“ESCC”) has been approved.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.